Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|5|611-617

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.5, 2015-05, pp. : 611-617

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors

By  

Cancer Science, Vol. 109, Iss. 1, 2018-01 ,pp. : 193-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

By  

Cancer Science, Vol. 106, Iss. 11, 2015-11 ,pp. : 1590-1595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1714-1721

John Wiley & Sons Inc

Access to resources Recommend Favorite

MiR‐940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 819-824

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 883-890

John Wiley & Sons Inc

Access to resources Recommend Favorite